Jonathan Matz, M.D. Allergy & Immunology - Allergy Medicare: Accepting Medicare Assignments Practice Location: 5430 Campbell Blvd Ste 103, White Marsh, MD 21162 Phone: 410-933-9404 Fax: 410-933-9405 |
Dr. Sudhir Sekhsaria, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 5430 Campbell Blvd, Suite 103, White Marsh, MD 21162 Phone: 410-933-9404 Fax: 410-933-9405 |
Dr. Manav Singla, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 5430 Campbell Blvd, Suite 103, White Marsh, MD 21162 Phone: 410-933-9404 Fax: 410-933-9405 |
News Archive
Published today, during World Glaucoma Week 2020, a new study demonstrates how commercially available head mounted displays can be used to simulate the day-to-day challenges faced by people with glaucoma.
CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.
Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies, Inc., have discovered how to harness the power of bioelectricity to help improve skin rejuvenation. The new innovation, called CYTOMIMICâ„¢ Technology, is a proprietary, patented technology that combines essential minerals to deliver biological levels of electric signals similar to the skin's natural bioelectricity.
Does a reduction in the price of alcohol result in an increase in deaths due to alcohol? This was the subject of a study following a significant reduction in taxes in Finland in 2004 (30% for spirits, 3% for wine).The abolition of import quotas by the EU in 2004 also made it possible to import from other member countries and this led to an increase of approximately 10% in alcohol consumption in Finland.
Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures. This financing round also includes participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors.
› Verified 4 days ago